Trials / Completed
CompletedNCT00809159
Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as treatment of moderate to severe ankylosing spondylitis (AS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AIN457 | AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A. |
| DRUG | Placebo | Placebo to AIN457 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2008-12-17
- Last updated
- 2015-12-09
- Results posted
- 2015-09-18
Locations
20 sites across 4 countries: United States, Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00809159. Inclusion in this directory is not an endorsement.